Tricida Announces Administrative Stop of the VALOR-CKD Trial
Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022 SOUTH SAN FRANCISCO,…
Month: May 2022
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing…
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring…
Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years
Randomized Disrupt PAD III Study Finds Superior Vessel Preparation Leads to Excellent Long-Term Outcomes and…
Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER,…
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual…
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a…
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR),…
Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3
BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC50 values across key FLT3…
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected…
Enlivex to Present at the H.C. Wainwright Global Investment Conference
Nes-Ziona, Israel, May 19, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad…
Avadel to Present Clinical Data for FT218 at SLEEP 2022
DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical…
Umoja Biopharma Presents New Preclinical Data at ASGCT 2022 Annual Meeting on its VivoVec Platform Describing Preclinical Safety Data for UB-VV100 Product Candidate, VivoVec Engineering for Improved in vivo CAR T cell Generation and Development of a Scalable Manufacturing Platform
UB-VV100 preclinical safety data demonstrates overall low risk for off target transduction and has a…
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
PORTLAND, Maine, May 19, 2022 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”),…
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM”…
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
Independent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns…
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)Â Â
Company announcement – No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3…
iSpecimen Presents New Research to Optimize Biobanking at International Society for Biological and Environmental Repositories 2022 Annual Meeting
Company Gave Three Presentations, Including Oral Discussion on How New Technology Can Support the “Just-in-Time”…